Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS)

View ORCID ProfileDM Favara, A Cooke, R Doffinger, S Houghton, I Budriunaite, S Bossingham, K McAdam, P Corrie, N Ainsworth
doi: https://doi.org/10.1101/2020.06.22.20136838
DM Favara
1Department of Oncology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
2Department of Oncology, The Queen Elizabeth Hospital, The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust, Kings Lynn, UK
3Department of Oncology, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for DM Favara
  • For correspondence: df411@cam.ac.uk
A Cooke
4Cambridge Clinical Laboratories, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Doffinger
5Department of Immunology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Houghton
5Department of Immunology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I Budriunaite
6Tissue Typing Laboratory, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Bossingham
6Tissue Typing Laboratory, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K McAdam
1Department of Oncology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
7Department of Oncology, Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Corrie
1Department of Oncology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N Ainsworth
2Department of Oncology, The Queen Elizabeth Hospital, The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust, Kings Lynn, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The global SARS-CoV-2 (COVID-19) pandemic has caused substantial worldwide mortality. At present, there is no data regarding oncologist-specific SARS-CoV-2 infection/immunity rates in the United Kingdom (UK) which might impact planning for the management of potentially immunosuppressed cancer patients. Here, we present the first results from the COVID-19 Serology in Oncology Staff (CSOS) study with the aim of informing non-surgical oncology management guidelines.

Methods Patient-facing staff working in an oncology department during the COVID-19 pandemic at a large district general hospital in the East of England were invited to participate. Samples were collected during the first week of June 2020: blood for SARS-COV-2 antibody testing using a rapid lateral flow point of care (POC) assay and a laboratory Luminex based assay, as well as a nasopharyngeal swab for SARS-CoV-2 PCR testing. Participant characteristics were also collected.

Results Seventy participants were recruited: nurses (45/70; 64.3%), doctors (15/70; 21.2%), and other patient-facing staff (10/70; 14.3%). The majority were female (61/70; 87.1%) with a mean age of 42 years (median 41; range 23-64 years). A minority were smokers (9/70; 10%) or had chronic underlying health conditions (16/70; 22.9%), the commonest being asthma. All participants were nasopharyngeal-swab PCR negative, although 4/70 (5.7%) had previously tested positive by NHS testing undertaken during the preceding months. 15/70 (21.4%) had positive SARS-CoV-2 antibodies using the Luminex test. Nurses had the highest incidence of positive antibodies (13/45; 28.9%), with a lower incidence in doctors (2/15; 13.3%) although this difference was not statistically significant (Fischer’s exact test p=0.3). No receptionists had positive antibody tests. All four participants with a previously reported positive PCR test were antibody-positive. 9/15 (60%) of antibody-positive participants reported previous symptoms suggestive of SARS-CoV-2 infection: a 3.6-fold higher odds than antibody-negative participants, of whom 16/55 reported symptoms (p=0.03). The mean duration of symptoms was 11 days (median 11; range 1-35 days) and the mean time from resolution of reported previous symptoms to antibody testing was 48.4 days (median 46; range 1-123 days).

Conclusion This study establishes the SARS-CoV-2 exposure and carriage rate amongst patient-facing staff working in the oncology department of a large UK general hospital during the pandemic. These results may help inform UK national oncology patient management prior to the development of a viable vaccine or treatment.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the Oncology Department Charity Fund at the Queen Elizabeth Hospital NHS Foundation Trust, the Oncology Department Research Fund at Peterborough City Hospital, North West Anglia NHS Foundation Trust, and the Addenbrooke's Charitable Trust. All authors declare no conflict of interest.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval for the study was granted by the United Kingdom's Health Research Authority (HRA) (IRAS: 284231; 26/5/2020). Hospital approval was granted by the Queen Elizabeth Hospital King's Lynn NHS Foundation Trust R&D Department (Ref: 9/20; 28/5/2020).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available following reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted June 23, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS)
DM Favara, A Cooke, R Doffinger, S Houghton, I Budriunaite, S Bossingham, K McAdam, P Corrie, N Ainsworth
medRxiv 2020.06.22.20136838; doi: https://doi.org/10.1101/2020.06.22.20136838
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS)
DM Favara, A Cooke, R Doffinger, S Houghton, I Budriunaite, S Bossingham, K McAdam, P Corrie, N Ainsworth
medRxiv 2020.06.22.20136838; doi: https://doi.org/10.1101/2020.06.22.20136838

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (157)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (852)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8527)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1731)
  • Geriatric Medicine (166)
  • Health Economics (370)
  • Health Informatics (1232)
  • Health Policy (615)
  • Health Systems and Quality Improvement (465)
  • Hematology (196)
  • HIV/AIDS (367)
  • Infectious Diseases (except HIV/AIDS) (10258)
  • Intensive Care and Critical Care Medicine (550)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (209)
  • Neurology (1662)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (321)
  • Occupational and Environmental Health (450)
  • Oncology (918)
  • Ophthalmology (261)
  • Orthopedics (99)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (532)
  • Pharmacology and Therapeutics (245)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1751)
  • Public and Global Health (3814)
  • Radiology and Imaging (620)
  • Rehabilitation Medicine and Physical Therapy (316)
  • Respiratory Medicine (518)
  • Rheumatology (204)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (188)
  • Toxicology (36)
  • Transplantation (99)
  • Urology (74)